[Expression of Serum HMGB-1 in Patients with Secondary Hemo-phagocytic Lymphohistiocytosis and Its Clinical Significance].

• DOI: 10.7534/j.issn.1009-2137.2016.03.044
• Publication Date: 2016-06-01
• Authors: Dongjiao Wang; Jujuan Wang; Meng Song; Xin Gao; Limin Duan; Tian Tian; Hong-Xia Qiu
• Keywords: Clinical Significance; White blood cell; Aspartate transaminase; Erythrocyte sedimentation rate; Hemophagocytic Lymphohistiocytosis

To investigate the expression levels and clinical significance of serum high mobility group box 1 (HMGB-1) in patients with secondary hemophagocytic lymphohistiocytosis (sHLH).Serum HMGB-1 were determined by using enzyme linked immunosorbent assays (ELISA) 51 sHLH 15 healthy contrlols. Other laboratory data, including soluble interleukin-2 receptor (sCD25), white blood cells (WBC), hemoglobin (Hb), platelet (Plt), fibrinogen (FIB), lactate dehydrogenase (LDH), triglyceride (TG), alanine transaminase (ALT), aspartate aminotransferase (AST), ferritin (SF), C reactive protein (CRP), sedimentation rate (ESR) also collected.Serum newly diagnosed significantly higher than that control (P<0.01). Serum lymphoma-associated HLH (LHLH) non-HLH group, infection-associated (IHLH) autoimmune-associated (AHLH) (P<0.05); The remission lower (P<0.05), however, was not decreased progression/relapsed compared (P>0.05). positively correlated sCD25 (r=0.62, P<0.01) ESR (r=0.55, P<0.05). receiver operating characteristic curves (ROC) for controls produced a cutoff value at 15.3 µg/L, its 90% sensitivity 99% specificity, respectively. In addition, an optimal 27.4 µg/L LHLH (AHLH+IHLH) 96% 81% separately.Serum possesses important clinically disease diagnosis, differential evaluation nosographic activity treatment efficacy sHLH.